SCHEMBL929446

SCHEMBL929446

CC1c2ccc(C(=O)NC3CC3)n2CCN1C(=O)c1cc2ncc(Br)cn2n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 5/20 0.46
ALDH1A1 P00352 4/20 0.46
GAA P10253 2/20 0.46
MAPT P10636 2/20 0.46
ESR2 Q92731 5/20 0.45
HPGD P15428 1/20 0.45
TSHR P16473 1/20 0.45
RECQL P46063 1/20 0.43
POLB P06746 7/20 0.42
ESR1 P03372 3/20 0.42
CTDSP1 Q9GZU7 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
KMT2A Q03164 3/20 0.42
GRM5 P41594 7/20 0.42
KDM4E B2RXH2 3/20 0.42
RAB9A P51151 3/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
HSD17B10 Q99714 2/20 0.42
APOBEC3A P31941 1/20 0.42
NR4A1 P22736 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL929840 0.90 TDP1 (0.48) TDP1ALDH1A1GAAMAPTESR2
SCHEMBL928728 0.90 GRM5 (0.40) TDP1ALDH1A1GAAMAPTESR2
SCHEMBL929943 0.88 RECQL (0.48) TDP1ALDH1A1GAAMAPTESR2
SCHEMBL927955 0.88 TDP1 (0.46) TDP1ALDH1A1GAAMAPTESR2
SCHEMBL929942 0.88 TDP1 (0.48) TDP1ALDH1A1GAAMAPTESR2
SCHEMBL3816915 0.86 KDM4E (0.35) ALDH1A1GAAMAPTKMT2AKDM4E
SCHEMBL929127 0.84 ALDH1A1 (0.54) TDP1ALDH1A1GAAMAPTESR2
SCHEMBL928895 0.84 ALDH1A1 (0.53) TDP1ALDH1A1GAAMAPTESR2
SCHEMBL928294 0.84 ALDH1A1 (0.53) TDP1ALDH1A1GAAMAPTESR2
SCHEMBL927805 0.83 ALDH1A1 (0.52) TDP1ALDH1A1GAAMAPTESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2085398-A1 Pyrazolopyrimidines, a process for their preparation and their use as medicine Merz Pharma GmbH & Co. KGaA (DE) 2009-08-05 EP claimed
US-20110003820-A1 PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE MERZ PHARMA GMBH & CO. KGAA (DE) 2011-01-06 US disclosed
EP-2247590-A1 PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE Merz Pharma GmbH & Co. KGaA (DE) 2010-11-10 EP disclosed
WO-2009095254-A1 PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE MERZ PHARMA GMBH & CO. KGAA (DE) 2009-08-06 WO disclosed
EP-2085398-A1 Pyrazolopyrimidines, a process for their preparation and their use as medicine Merz Pharma GmbH & Co. KGaA (DE) 2009-08-05 EP disclosed
EP-2085398-A1 Pyrazolopyrimidines, a process for their preparation and their use as medicine Merz Pharma GmbH & Co. KGaA (DE) 2009-08-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003820-A1 PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE GRM5, GRIK5, GRK5 TDP1 1875/4885ALDH1A1 2888/4885GAA 3740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.